A new science-business paradigm in anticancer drug development

Author： Blagosklonny M.V.  

Publisher： Elsevier

ISSN： 0167-7799

Source： Trends in Biotechnology, Vol.21, Iss.3, 2003-03, pp. : 103-106

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Time for a new business model?

By Friedman Yali  

Journal of Commercial Biotechnology, Vol. 16, Iss. 1, 2010-01 ,pp. : 1-2

Palgrave Macmillan Ltd

Access to resources Recommend Favorite

Metallo-supramolecular modules as a paradigm for materials scienceInvited paper.

By  

Science and Technology of Advanced Materials, Vol. 9, Iss. 1, 2008-01 ,pp. : 113-137

IOP Publishing

Access to resources Recommend Favorite

Production and Characterization of γ-Polyglutamic Acid Nanoparticles for Controlled Anticancer Drug Release

By Manocha Bhavik   Margaritis Argyrios  

Critical Reviews in Biotechnology, Vol. 28, Iss. 2, 2008-06 ,pp. : 83-99

Informa Healthcare

Access to resources Recommend Favorite

PH responsive polypeptide based polymeric micelles for anticancer drug delivery

By  

Journal Of Biomedical Materials Research. Part A, Vol. 103, Iss. 9, 2015-09 ,pp. : 3045-3053

John Wiley & Sons Inc

Access to resources Recommend Favorite

Best Practices in Biotechnology Business Development

By Lydecker Hans-Erik Hamid  

Journal of Commercial Biotechnology, Vol. 14, Iss. 4, 2008-10 ,pp. : 365-367

Palgrave Macmillan Ltd

Access to resources Recommend Favorite